GlaxoSmithKline Pharmaceuticals Dirección
Dirección controles de criterios 3/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Bhushan Akshikar
Chief Executive Officer (CEO)
₹66.9m
Compensación total
| Porcentaje del salario del CEO | 21.7% |
| Permanencia del CEO | 1.9yrs |
| Participación del CEO | n/a |
| Permanencia media de la dirección | 2.1yrs |
| Promedio de permanencia en la Junta Directiva | 6.6yrs |
Actualizaciones recientes de la dirección
Recent updates
GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Nov 01
We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Can Manage Its Debt With Ease
Aug 29The GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 05Investors Appear Satisfied With GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Prospects As Shares Rocket 26%
Jun 01With EPS Growth And More, GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Makes An Interesting Case
May 05GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Popularity With Investors Is Clear
Apr 14Revenue Miss: GlaxoSmithKline Pharmaceuticals Limited Fell 5.9% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
Feb 15Is Now The Time To Put GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) On Your Watchlist?
Jan 18GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Investors Are Less Pessimistic Than Expected
Dec 28Here's Why We Think GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Might Deserve Your Attention Today
Oct 05Is GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Using Too Much Debt?
Sep 12GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Has A Pretty Healthy Balance Sheet
Mar 17Does GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Have A Healthy Balance Sheet?
Sep 02GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Seems To Use Debt Rather Sparingly
Mar 02The GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Share Price Is Up 32% And Shareholders Are Holding On
Mar 20Does GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) Have A Place In Your Dividend Portfolio?
Feb 27Declining Stock and Decent Financials: Is The Market Wrong About GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)?
Feb 06What Type Of Shareholders Make Up GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Share Registry?
Jan 11
GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Shareholders Have Enjoyed A 26% Share Price Gain
Dec 06Earnings Miss: GlaxoSmithKline Pharmaceuticals Limited Missed EPS By 48% And Analysts Are Revising Their Forecasts
Nov 01Tread With Caution Around GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) 1.3% Dividend Yield
Oct 29What Kind Of Shareholders Hold The Majority In GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Shares?
Sep 29If You Had Bought GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) Stock A Year Ago, You Could Pocket A 30% Gain Today
Aug 30Is GlaxoSmithKline Pharmaceuticals Limited's (NSE:GLAXO) Recent Performancer Underpinned By Weak Financials?
Aug 02It Might Not Be A Great Idea To Buy GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO) For Its Next Dividend
Jul 12Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | ₹7b |
| Jun 30 2024 | n/a | n/a | ₹6b |
| Mar 31 2024 | ₹67m | ₹15m | ₹6b |
| Dec 31 2023 | n/a | n/a | ₹5b |
| Sep 30 2023 | n/a | n/a | ₹6b |
| Jun 30 2023 | n/a | n/a | ₹6b |
| Mar 31 2023 | ₹34m | ₹4m | ₹6b |
Compensación vs. Mercado: La compensación total ($USD793.32K) de Bhushan está en línea con el promedio de empresas de tamaño similar en el mercado Indian ($USD774.00K).
Compensación vs. Ingresos: La compensación de Bhushan ha aumentado más de un 20% en el último año.
CEO
Bhushan Akshikar
1.9yrs
Permanencia
₹66,885,000
Compensación
Mr. Bhushan Akshikar is Managing Director of GlaxoSmithKline Pharmaceuticals Limited from December 1, 2022. He served as Additional Director of GlaxoSmithKline Pharmaceuticals Limited since March 18, 2021...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Executive Director | 1.9yrs | ₹66.89m | sin datos | |
| Whole-Time Director & CFO | 2.6yrs | ₹68.92m | sin datos | |
| Executive Vice President of Human Resources | 3.9yrs | ₹37.40m | sin datos | |
| Vice President of Technology | less than a year | sin datos | sin datos | |
| VP of Administration & Real Estate and Company Secretary | no data | ₹11.57m | sin datos | |
| Executive Vice President of Legal | 2.8yrs | sin datos | sin datos | |
| Vice President of Ethics & Compliance | 1.8yrs | sin datos | sin datos | |
| Executive Vice President of Communications & Government Affairs | 7.6yrs | sin datos | sin datos | |
| Executive Vice-President of Regulatory Affairs | no data | sin datos | sin datos | |
| Executive Vice-President of Adult Vaccines | 2.3yrs | sin datos | sin datos | |
| Executive Vice President of General Medicines | 1.9yrs | sin datos | sin datos | |
| Commercial Head - Paediatric Vaccines | 1.8yrs | sin datos | sin datos |
2.1yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de GLAXO se considera experimentado (2.1 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| MD & Executive Director | no data | ₹66.89m | sin datos | |
| Whole-Time Director & CFO | 2.6yrs | ₹68.92m | sin datos | |
| Non-Executive Chairperson | 5.6yrs | ₹3.25m | sin datos | |
| Independent Director | 2.5yrs | ₹2.65m | sin datos | |
| Non-Executive Independent Director | 15.3yrs | ₹2.70m | sin datos | |
| Non Executive Director | 7.6yrs | sin datos | sin datos | |
| Non-Executive Independent Director | 14.1yrs | ₹2.70m | sin datos | |
| Non-Executive Independent Director | 13yrs | ₹2.45m | sin datos | |
| Non-Executive & Independent Director | 4.5yrs | ₹2.45m | sin datos |
6.6yrs
Permanencia media
68.5yo
Promedio de edad
Junta con experiencia: La junta directiva de GLAXO se considera experimentada (6.6 años de antigüedad promedio).